A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

This study is comparing a new drug (BL-B01D1, an antibody-drug conjugate) to the investigator's choice of chemotherapy in women with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer that has returned after prior treatment. **You may be eligible if...** - You are 18 or older with confirmed epithelial ovarian, fallopian tube, or primary peritoneal cancer - Your cancer has come back despite platinum-based chemotherapy (platinum-resistant recurrence) - You have received 1–3 prior lines of treatment and your cancer is progressing - You have at least one measurable tumor and good organ function (ECOG 0–1) - If your tumor tests positive for FRα, you must have already received mirvetuximab soravtansine **You may NOT be eligible if...** - You received chemotherapy or targeted therapy within the past 4 weeks - You have severe heart problems (ejection fraction below 50%) - You are pregnant or breastfeeding - Your cancer has unresolved serious side effects from prior treatment above grade 1 Talk to your doctor to see if this trial is right for you.